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Robert Cusimano ea–eDivision of Cardiovascular Surgery, Toronto General Hospital and the University of Toronto, Toronto, Ontario, CanadaBackground: Post-cardiotomy shock (PCS) has a complex etiology. Although treatment with inotrops and intra-aortic
balloon pump (IABP) support improves cardiac performance, end-organ injuries are common and lead to prolonged
ICU stay, extended hospitalization and increased mortality. Early consideration of mechanical circulatory support may
prevent such complications and improve outcome.
Methods: Between January 1997 and January 2002, 321 patients required IABP and inotropic support for PCS fol-
lowing coronary artery bypass grafting (CABG) at our institution. Perioperative variables including age, mixed
venous saturation (MVO2), inotropic requirements and LV function were analyzed using multivariate statistical
methods. All explanatory variables with a univariate p value <0.10 were entered into a stepwise logistic regression
model to predict hospital mortality. Odds ratios from significant variables (p < 0.05) in the regression model were
used to compose a risk score.
Results: Overall hospital mortality was 16%. The independent risk factors for mortality in this population were:
MVO2 < 60% (OR = 3.2), milrinone > 0.5 lg/kg/min (OR = 3.2), age > 75 (OR = 2.7), adrenaline > 0.1 lg/kg/min
(OR = 1.5). A 15-point risk score was developed based on the regression model. Hospital mortality in patients with
a score >6 was 46% (n = 13/28), 3–6 was 31% (n = 9/29) and <3 was 11% (n = 29/264).
Conclusions: A significant proportion of patients with PCS continue to face high mortality despite IABP and ino-
tropic support. Advanced age, heavy inotropic dependency and poor oxygen delivery all predicted increased risk for
death. Further investigation is needed to assess whether early institution of VAD support could improve outcome in
this high-risk group of patients.
 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Despite advances in cardiopulmonary bypassand myocardial protection techniques,
post-cardiotomy shock (PCS) continues to occur
in about 4% of all patients undergoing cardiac sur-
gery. PCS manifests as systolic blood pressure
(SBP) <90 mmHg and cardiac index (CI) <2.2 L/
min/m2 despite inotropic support and carries a
very high mortality rate. The use of inotropic
and intra-aortic balloon pump (IABP) support is
the first line of therapy in these patients.
Unfortunately, despite this therapy a significant1016–7315  2012 King Saud University.
Production and hosting by Elsevier B.V. All rights reserved.
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doi:10.1016/j.jsha.2012.02.005proportion of patients with PCS continue to
develop end organ damage resulting in increased
morbidity and mortality.
We aim in our study to design a predictive
model to identify patients with post-cardiotomy
shock whose clinical condition will continue to
deteriorate despite the aggressive use of inotropic
and IABP support and therefore may benefit
from early institution of mechanical circulatory
support prior to the development of end organ
failure.
Figure 1. A receiver–operator curve created using the assigned weights to examine the relation between true positive values (sensitivity) and false
positive values (1 minus specificity). The area of the graph that lies beneath the curve is representative of test accuracy.
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DATA sources
A retrospective review of hospital charts was
performed in all patients who required IABP for
the support of PCS at our institution between Jan-
uary 1997 and January 2002. Pertinent peri-opera-
tive clinical and demographic data are entered
prospectively into an institutional database for
all patients. We identified 321 patients who re-
quired inotropic and IABP support post-opera-
tively and their data was analyzed. Patients in
whom an IABP had been implanted pre-opera-
tively were excluded.
Statistical analysis
Discrete variables were expressed as their abso-
lute or percentage frequency values and were
compared with v2 exact test. Continuous variables
demonstrating a normal distribution were ex-
pressed as mean ± standard deviation (SD) and
were compared using Student’s T test. We in-
cluded the following variables in our univariate
analysis: age, gender, IABP timing, urgency of sur-
gery, renal function, preoperative and postopera-
tive Myocardial infarction, left ventricular
ejection fraction (Grade 1: LVEF > 60%, Grade 2:
LVEF 40–59%, Grade 3: LVEF 20–39%, Grade 4:
LVEF < 20%), mixed venous oxygen saturations
(MVO2), inotropic support including milrinone,
dopamine, adrenaline and noradrenaline. Those
variables that demonstrated significant correlation
with mortality (p < 0.1) were entered into a multi-
variate, stepwise logistic regression model. Odds
ratios from significant variables (p < 0.05) in theregression model were used to compose a risk
score. On the basis of these statistical relations, a
risk factor selection scale (RFSS) was developed
by computing appropriate weights for each risk
factor according to their odds ratio. These weights
were summed to compose a variable score ranging
from 0 (lowest risk) to 15 (highest risk) for each pa-
tient. The mean probability of mortality was calcu-
lated for each score. We performed a receiver–
operator characteristic analysis (ROC) where true
positive values (sensitivity) are plotted against
false positive values (1 minus specificity) to assess
whether our scoring system is accurate in predict-
ing outcomes and to chose the appropriate scale
point at which IABP and Inotropic support is inad-
equate for patient survival. (Fig. 1).Results
During the study period, 9863 patients under-
went isolated coronary bypass surgery at our insti-
tution. Of these, 321 (3.3%) patients developed
post-cardiotomy shock. Overall mortality in this
cohort was 16% (n = 51/321). Multivariate analysis
identified four independent predictors of opera-
tive mortality. These included patient age,
MVO2, the need for milrinone or adrenaline. A
score was then developed by using these four
variables with weights assigned according to their
odds ratios. (Table 1) A 15-point risk score was
developed based on the regression model. Hospi-
tal mortality in patients with a score >6 was 46%
(n = 13/28), 3–6 was 31% (n = 9/29) and <3 was
11% (n = 29/264). (Fig. 2).
Table 1. Significant parameters on multivariate analysis and
the assigned weights according to their odds ratio.
Significant multivariate
factors
Odds
ratio
95%
confidence
intervals
Risk
score
Age 675 yrs 0
Age >75 yrs 2.7 1.3–5.9 3
MVO2 P60% 0
MVO2 <60% 3.2 1.2–8.9 3
Milrinone 60.5 lg/kg/min 0
Milrinone >0.5 lg/kg/min 3.2 1.3–8.1 3
Adrenaline 60.1 lg/kg/min 0
Adrenaline 0.1–0.2 lg/kg/min 3.8 1.5–9.4 4
Adrenaline >0.2 lg/kg/min 5.5 1.9–16.4 6
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Figure 2. The probability of survival dependent on the score.
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The first clinical use of an intra-aortic balloon
pump (IABP) was by Kantrowitz in 1968 for the
treatment of three patients with refractory post-
infarction cardiogenic shock [1]. Since that time,
the role of IABP has expanded and its indications
widened to include pre-operative and post-opera-
tive cardiac support. It is the simplest and most
commonly utilized cardiac assist device and its
use is standard in most cardiac surgical centers.
Post-cardiotomy shock continues to occur in
2–6% of patients undergoing open heart surgery
and is associated with a high mortality. In this
series, 3.3% of patients developed PCS following
isolated CABG with a hospital mortality of 16%.
Myocardial support with inotrops and early
implantation of an IABP improves patient hemo-
dynamics. Weaning from cardiopulmonary
bypass is facilitated in up to 90% of cases with sub-
sequent removal of the IABP in 60–70% [2–5]. How-
ever, some patients continue to have low cardiac
output despite maximumpharmacologic and IABP
support, resulting in eventual end organ ischemia,
multi-organ failure and death. Often, we witness
cardiac recovery in five to seven days (as assessed
by the ability to wean inotropic stimulation), yet
by this time patients have suffered irreversible in-
jury to other end-organs. Early use of other formsof cardiac support such as extracorporeal mem-
brane oxygenation (ECMO) and left ventricular as-
sist devices (LVADs) has been demonstrated to
improve patient outcome by supporting their
hemodynamics and preventing end organ injury
until either recovery of native cardiac function or
subsequent heart transplantation [6–11]. Timely
institution ofmechanical circulatory support is crit-
ical to patient survival, yet does involve consider-
able morbidity and resource utilization. Surgeons
are reluctant to proceed to VAD insertion in pa-
tients who may not require this degree of support,
yet are aware that a very short window of opportu-
nity exists to intervene in this high risk patient pop-
ulation. We have applied VAD for patients in post-
cardiotomy shock in our institution. Hospital sur-
vival was only 50%, similar to the survival reported
in the literature. Because of those poor results, we
intended in our current study to analyze the factors
affecting outcome in an attempt to create guide-
lines for early introduction of ventricular assist de-
vice support that should lead to improved survival.
We aimed in this study to identify patients with
PCSwho are unlikely to survive despite heavy ino-
tropic and IABP support. Although it may initially
appear that all of these patients are being
adequately supported, the high mortality (16%)
indicates that more aggressive intervention is re-
quired in some subsets. We found that advanced
age, poorMVO2 (as a marker of myocardial perfor-
mance) and the need for high dose milrinone and
adrenaline predicted poor outcome. These are the
patients that will likely benefit from early institu-
tion of mechanical circulatory support as a bridge
to recovery or transplantation. Alternatively, in
non-transplant eligible patients, crucial end-of-life
decisions may be facilitated with a greater under-
standing of the natural history of PCS.
In our series, hospital mortality correlated di-
rectly with the patient’s risk score. A score >6 was
associated with a mortality of 46% compared to a
mortality of 11% with a score <3. In patients with
an intermediate score [3–6], hospital mortality
was 31%. Recent single center reports of circulatory
support for PCS have documented a hospital sur-
vival of 25–50% [7–10]. All of these reports have im-
plied that earlier institution of mechanical support
would have improved overall survival rates. The
data from the present study along with the pub-
lished results of device therapy for PCS suggest
that patients who have scores >6 despite IABP
and inotropic support are likely to benefit from de-
vice placement prior to development of end organ
damage. Samuels et al. derived a similar score from
their experience with the ABIOMED BVS5000
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need for multiple high dose inotrops (despite
apparently adequate hemodynamics) was associ-
ated with mortality in excess of 70%.
Postoperative mortality is dependent on preop-
erative, intraoperative and postoperative vari-
ables. There are predictive models, such as the
Society of Thoracic Surgeons risk model, that in-
clude all preoperative risk factors and are helpful
in estimating operative mortality and will influ-
ence the surgeon’s decision to operate on the pa-
tient. After that decision is made, the patient
may still have post-cardiotomy shock and require
IABP and inotropic support; and at that point, the
variables that we noted in our current series will
influence patient’s survival. Our aim in this study
was to create a predictive model for recovery in
patients requiring IABP and heavy inotropic sup-
port following CABG. At that stage, many preop-
erative variables are not relevant at this point.
The choice of device placement will depend on
several patient factors and the likelihood of myo-
cardial recovery. A patient’s age may influence
the available options. In our series, patients
<75 years old had a mortality of 14% while pa-
tients >75 years old had a mortality of 27%
(p = 0.02). In most programs, patients over the
age of 75 are not candidates for cardiac transplan-
tation and the options will be limited to prolonged
device support (as destination therapy) versus
continued IABP and pharmacologic support with
the attendant high morbidity and mortality. Other
patient factors such as size, anatomy and co-mor-
bid issues will influence the type of support.
Although we did not directly address the issue
of uni- vs. biventricular support, most authors
contend that biventricular support is favored in
the situation of acute postcardiotomy shock
[8,9,12,13].Conclusions
Postcardiotomy cardiogenic shock continues to
be associated with a high mortality rate. Aggres-
sive inotropic and IABP support may improve pa-
tient survival; however, we have identified a
cohort of patients that continue to face almost a
50% risk of end organ failure and death. Advanced
patient age, high milrinone and adrenaline
requirements and persistent low mixed venous
oxygen saturations are associated with pooroutcome. Utilizing the prognostic score described
in this study will help identify patients who may
benefit from early mechanical circulatory support
as a bridge to either myocardial recovery or car-
diac transplantation.Disclosures
This study was supported in part by the Second
Robert E. Gross Scholarship from the American
Association for Thoracic Surgery (VR).
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